Previous Article | Next Article 
Journal of Clinical Microbiology, October 2001, p. 3537-3540, Vol. 39, No. 10
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3537-3540.2001
Quantitative, Fluorogenic Probe PCR Assay for
Detection of Human Herpesvirus 8 DNA in Clinical Specimens
Felicia R.
Stamey,
Mitesh M.
Patel,
Brian P.
Holloway, and
Philip E.
Pellett*
Centers for Disease Control and Prevention,
Atlanta, Georgia 30333
Received 28 February 2001/Returned for modification 6 June
2001/Accepted 28 June 2001
 |
ABSTRACT |
A quantitative, fluorescence-based PCR assay (TaqMan-based
system) was developed for detection of human herpesvirus 8 (HHV-8) DNA
in clinical specimens. Primers and probes chosen from each of five
10-kb segments from the unique region of the HHV-8 genome were
evaluated for sensitivity with dilution series of DNA extracted from a
cell line (BCBL-1) that harbors HHV-8 DNA. Although several of the
primer-probe sets performed similarly with BCBL-1 DNA that had been
diluted in water, their performance differed when target DNA was
diluted in a constant background of uninfected cell DNA, an environment
more relevant to their intended use. The two best primer-probe
combinations were specific for HHV-8 relative to the other known
human herpesviruses and herpesvirus saimiri, a closely related
gammaherpesvirus of nonhuman primates. PCRs included an enzymatic
digestion step to eliminate PCR carryover and an exogenous internal
positive control that enabled discrimination of false-negative from
true-negative reactions. The new assays were compared to conventional
PCR assays for clinical specimens (saliva, rectal brushings, rectal
swab specimens, peripheral blood lymphocytes, semen, and urine) from
human immunodeficiency virus-positive patients with or without
Kaposi's sarcoma. In all instances, the new assays agreed with each
other and with the conventional PCR system. In addition, the
quantitative results obtained with the new assays were in good
agreement both for duplicate reactions in the same assay and between assays.
 |
INTRODUCTION |
Human herpesvirus 8 (HHV-8), also
known as Kaposi's sarcoma (KS)-associated herpesvirus, is the
etiologic agent of KS; it has been associated with a subset of body
cavity lymphomas known as primary effusion lymphoma and multicentric
Castleman's disease (reviewed in references 8, 13, and
15). Many aspects of HHV-8 natural history are unknown,
especially with regard to viral load in various bodily fluids in
relation to time after infection, immune function, and therapy directed
either at the virus, the end-organ disease, or the immune system. Study
of such relationships requires reproducible, accurate, and precise
methods for determining DNA concentrations. Semiquantitative and robust
quantitative systems have been described, but in general they are not
easily adapted for high throughput and are susceptible to PCR
contamination due to both the number of manipulations required and the
need to manipulate amplified products to enable detection (2, 3,
6, 7).
Methods have been developed for the detection of PCR products that
enable continuous monitoring of product accumulation during PCR, e.g.,
TaqMan, LightCycler, fluorescence resonance energy transfer probes
(1, 5), and molecular beacons (17); these methods are collectively referred to as real-time PCR. These methods do
not require specimen manipulation after reaction assembly, thereby
substantially reducing the possibility of PCR carryover contamination
and reducing net labor. In addition, these systems can be adapted to
yield accurate and precise quantitative information over a dynamic
range that spans 6 orders of magnitude. Several assays based on the
TaqMan system have been described for HHV-8 (4, 11, 12).
While these systems have clear utility, many aspects of their
performance have not been defined, and only a few primer-probe
combinations have been evaluated.
Here we describe the development and validation of a quantitative
TaqMan-based system that is based on primer-probe combinations chosen
from primer-probe sets derived from five different segments of the
HHV-8 genome. Methods were incorporated for preventing amplimer
carryover contamination and for evaluating amplification efficiency.
The optimized assays were compared to each other and to a standard
qualitative PCR system that used radioactivity-based Southern blot
amplimer detection.
 |
MATERIALS AND METHODS |
Patient specimens.
Patient specimens were obtained from
human immunodeficiency virus-positive patients, some with KS (P. E. Pellett et al., unpublished data). Specimens included
peripheral blood lymphocytes, semen, urine, rectal swab specimens,
rectal brushings, and saliva. Appropriate institutional approvals and
informed consents were obtained.
Primers and probes.
Primers and probes were chosen using
Primer Express software (PE Applied Biosystems, Foster City, Calif.).
Primers and probes were synthesized by standard phosphoramide chemistry
techniques at the Biotechnology Core Facility at the Centers for
Disease Control and Prevention. Probes were labeled at the 5' end with the reporter molecule 6-carboxyfluorescein (FAM) and at the 3' end with
the quencher 6-carboxytetramethylrhodamine. All TaqMan probes were
synthesized with a 3' phosphate group to block extension by
Taq polymerase.
TaqMan PCR.
TaqMan reagents and enzymes were obtained from
PE Applied Biosystems. Each 50-µl PCR contained 1× TaqMan universal
PCR master mix containing uracil-N-glycosylase (AmpErase),
500 nM each HHV-8 primer, 100 nM HHV-8 probe, 0.2 fg of an exogenous
internal positive control DNA (TaqMan exogenous internal positive
control), 1× TaqMan exogenous IPC primer and probe (VIC-labeled
probe) mix, and 5 µl of template DNA. Following 2 min of incubation
at 50°C for the activation of uracil-N-glycosylase, the
polymerase (Amplitaq Gold) was activated at 95°C for 10 min.
Forty cycles of PCR were done, each consisting of 95°C for 15 s
and 60°C for 1 min. Amplification was carried out with an ABI Prism
7700 sequence detection system (PE Biosystems, Foster City,
Calif.), which permitted continuous automated reading of fluorescence
intensities during PCR. Each PCR run contained numerous controls along
with the standard dilution curve, including six no-amplification
controls and six no-template controls. The dilutions of control
template used to generate the standard curve were run in
duplicate reactions, as were the unknown specimens. Data were analyzed
in both real-time and end-point plate read modes.
Control template for standard curve.
Purified BCBL-1 DNA
(QIAamp blood kit; Qiagen, Valencia, Calif.) was used to prepare the
standard curve. The HHV-8 genomic copy number was determined by
Southern blot comparisons between dilutions of the purified BCBL-1 DNA
and a plasmid of known concentration that contained an HHV-8 genomic
fragment by use of a phosphorimager. As determined in a Southern blot
reconstruction experiment, relative to a purified plasmid containing an
HHV-8 genomic segment, there were approximately 25 copies of HHV-8 DNA
per cell in the preparation used for these experiments (E. C. Mar,
personal communication). The standard curve was generated based on
dilutions of this DNA (5 × 106 copies to
0.5 copy per reaction) in a constant background of 500 ng of DNA
purified from uninfected HLF cells per reaction and 0.2 fg of
the exogenous internal positive control DNA.
Internal positive control.
A 0.2-fg quantity of TaqMan
exogenous internal positive control was spiked into each unknown sample
and control template. This control enables true negatives to be
distinguished from false negatives due to PCR inhibition. In the PCR,
the target and internal positive control DNA are amplified
simultaneously. A negative result for the target and a positive result
for the internal positive control DNA indicate that no target sequence
is present. A negative result for each suggests PCR inhibition. The
amounts of internal positive control DNA and primers included in each
reaction were chosen by titration to be sufficient for consistent
detection of the internal positive control DNA amplification without
compromising the efficiency of the target DNA amplification. A post-PCR
plate read (end point) was done to collect one fluorescence scan per well for detection of the internal positive control DNA amplification. The internal positive control DNA is detected with a VIC-labeled probe,
allowing it to be discriminated from the HHV-8 DNA detected with the
FAM-labeled probe. Data acquisition and analysis were done using
sequence detection system software (version 1.6.3; PE Applied Biosystems).
 |
RESULTS |
Selection and preliminary evaluation of primers and probes.
Computer-based methods for choosing primers and probes do not take into
account important parameters, such as the sequence composition of the
complex mixture of DNA that is represented in a virus-infected
eucaryotic cell or the influence of secondary structure on the ability
of a segment of DNA to be amplified. Thus, experiments must be done to
evaluate the relative utility of computer-chosen primer-probe
combinations (10). Primer-probe combinations were chosen
that were among the best predicted within each of five 10-kb segments
that together span 50 kb of the HHV-8 genome. The different genomic
segments were targeted to obtain at least two primer-probe sets derived
from different genomic regions, to provide greater assurance that
potentially infectious virus is being detected, and to ensure that the
chosen sets represent theoretically and experimentally evaluated nearly
optimal sequences derived from sampling of a substantial portion of the
viral genome. Sequence analyses have indicated that this portion of the
genome is generally highly conserved among HHV-8 genomes obtained on different continents and from different diseases (9).
Criteria for the initial selection of primers included a G+C content of between 30 and 80%, avoidance of identical runs of a nucleotide, amplimer lengths of between 60 and 150 bp, a
Tm of ~58 to 60°C, and the absence of
more than two G's or C's at the 3' end. Probes were chosen to avoid
identical runs of a nucleotide, to not have a G at the 5' end, and to
have a Tm ~10°C higher than that of the corresponding primers (~68 to 70°C). In addition, several primer sets were chosen so that their reaction temperatures would be
the same for ease during optimization and eventual simultaneous use.
The amplimers chosen for experimental evaluation ranged in length from
67 to 125 bp (Table 1).
In initial experiments, primer concentrations and ratios were titrated
using a constant amount of purified BCBL-1 DNA (equivalent
to 2,400 copies) to determine the minimum primer concentrations
that yielded the
maximum magnitude of the signal generated (

Rn).
Primer
concentrations tested were 250, 500, and 750 nM. All probes
were used
at a concentration of 100 nM. The following primer concentrations
(for
the forward and reverse primers, respectively) worked best:
K5, 250 and
500 nM;
orf25, 500 and 500 nM;
orf37, 500 and 500
nM;
orf47, 500 and 750 nM; and
orf56, 500 and 500
nM.
Primer and probe sets were tested against dilutions of purified BCBL-1
DNA ranging from 5 × 10
6 copies/µl to 0.5 copy/µl. As summarized in Table
1, all of the
primer-probe
combinations performed well when the dilution was
done in water.
However, when the same template was diluted in
a background of 10 ng
per µl (500 ng per reaction) of DNA extracted
from uninfected cells
to mimic the actual conditions of low virus
concentrations in human
tissues and fluids, the primer-probe sets
based on orf25 and orf37 had
better values for both

Rn and the
threshold cycle of detection (Ct)
(Table
1). Standard curves
generated with these primers and a control
template diluted in
the presence of uninfected cell DNA had a
correlation coefficient
of approximately 0.99 over the range of 5 to
5 × 10
6 genomic copies (Table
1).
Exogenous internal coamplified positive control.
The use of an
exogenous internal coamplified positive control enables same-tube
evaluation of amplification efficiency, which reflects the presence of
PCR inhibitors. This is particularly useful with specimens such as
bodily fluids or tissues in which the cellular DNA load can vary widely
and in which the detection of a cellular gene by standard PCR can give
a false sense of the suitability of a template preparation for
detecting a viral DNA target that may be present at fewer than 1 copy
per 100,000 cells. We used a commercially available internal positive
control DNA that can be detected with a VIC-labeled probe that does not
interfere with the FAM-labeled probe used to detect HHV-8 DNA.
Titrations of the internal positive template sequence and its primers
and probes were done to identify concentrations that enabled reliable detection of the probe without interfering with the amplification of
viral DNA (data not shown). The internal positive control DNA could be
diluted 40-fold relative to the manufacturer's recommendations. The
recommended concentration of the probe worked the best (data not
shown). Under these conditions, the internal positive control could be
detected with no discernible effect on HHV-8 detection limits.
Specificity.
All of the primer-probe sequences were compared
with sequences in GenBank by using BlastN and BlastX; no obviously
significant matches to anything other than their intended HHV-8 targets
were identified. The orf25 and orf37 primer-probe
combinations were further tested for specificity in reactions that
included 105 genomic copies of each of the other
known human herpesviruses plus herpesvirus saimiri, a nonhuman primate
gammaherpesvirus closely related to HHV-8. As shown for
orf37 in Fig. 1, only HHV-8 gave a positive signal.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
Sensitivity and specificity of the orf37
TaqMan-based assay. Specificity reactions (shown in duplicate) included
105 genomic copies of each of the following: herpes simplex
virus type 1 (HSV-1), HSV-2, varicella-zoster virus (VZV), Epstein-Barr
virus (EBV), cytomegalovirus (CMV), HHV-6A, HHV-6B, HHV-7, HHV-8, and
herpesvirus saimiri (HVS).
|
|
Comparison with conventional PCR.
Having optimized for
sensitivity and specificity the primer-probe combinations, we compared
the orf25 and orf37 TaqMan-based PCR assays to
our conventional PCR assay. Patient specimens were obtained from human
immunodeficiency virus-positive patients, some of whom had KS.
Specimens included peripheral blood lymphocytes, semen, urine, rectal
swab specimens, rectal brushings, and saliva and were chosen as a
mixture of specimen types that had shown positive or negative
reactivity in our conventional PCR assay (16). There was
complete correlation between the TaqMan-based assays and the standard
assay (Table 2). Viral loads for
HHV-8-positive samples ranged from 13 copies/reaction to 1,530 copies/reaction. The results obtained from duplicate reactions were
very consistent (less than 2% variation from the mean), and the
quantitative values from the orf25 and orf37 assays were in
good agreement (Table 2). These results are further indicators of the
reproducibility of the assays.
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Comparison between conventional and TaqMan-based PCR
assays for detection of HHV-8 in clinical specimens
|
|
The highest concentration of control BCBL-1 DNA template used to
generate the standard curve typically results in an initial
Ct value of
14 cycles, indicating a significant increase in the

Rn. At the
detection limit, the control specimen containing approximately
five
copies of HHV-8 DNA usually has a Ct value of approximately
33 cycles.
All of the clinical specimens that were identified
as positive in the
conventional PCR assay had Ct values of between
26 and 32 cycles in the
two TaqMan-based assays. All of the clinical
specimens that were
identified as negative in the conventional
PCR assay had Ct values of
greater than 35 cycles in the two TaqMan-based
assays.
 |
DISCUSSION |
Quantitative, fluorescence-based assays were developed for PCR
detection of HHV-8 DNA in various human body fluids. The new assays
have numerous advantages over conventional PCR assays that require
additional steps for amplimer detection, such as Southern blotting
following gel electrophoresis or enzyme-linked immunosorbent assay.
These advantages include (i) reduced opportunity for carryover contamination from prior PCR experiments because reactions are performed with closed 96-well plates that are never opened after reactions are set up, (ii) inclusion of an exogenous internal positive
control that allows discrimination of true negatives from false
negatives due to PCR inhibition, and (iii) ability to complete
experiments in 1 day with a rigorous quantitative result. In addition,
the chance of PCR carryover contamination was further reduced by
inclusion of an enzymatic step to digest stray amplimers from previous
reactions. The linear range of the assays was between 5 and 5 × 106 target copies; variability between duplicate
specimens tested with the same assay was less than 2%, with
independent quantitative assays being in agreement within a factor of
approximately 2. The simplicity of the system makes it useful for
application to large numbers of samples for the quantitation of HHV-8
in clinical specimens.
Lallemand et al. (4) recently described a TaqMan-based
HHV-8 quantitative PCR system that was based on a single primer set
derived from one HHV-8 gene (orf73). They quantitated
cellular DNA in a separate reaction, a process which enabled them to
report results in terms of viral genome copies per cell; for some
purposes, this would be a straightforward useful addition to the method described here. However, the use of a cellular gene as a positive control target can provide false reassurance that the template is
suitable for the amplification of low-copy-number targets, as
exemplified by the possibility of only 1 in 100,000 cells being infected with HHV-8. To address this situation, we incorporated a
titrated amount of an exogenous internal positive control that enabled
us to discriminate false-negative from true-negative reactions, without
competing for reaction resources or giving a false sense of security
regarding template suitability.
 |
ACKNOWLEDGMENTS |
We thank Ruth Ann Tucker and David Swan for in-depth discussions
and guidance during the initial stages of developing the TaqMan-based
system, Eng-Chun Mar for determining the HHV-8 copy number in BCBL-1
DNA, Sheila Dollard for sharing results obtained by conventional PCR,
and the Atlanta HHV-8 Working Group for collecting the clinical specimens.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Centers for
Disease Control and Prevention, 1600 Clifton Rd. G18, Atlanta, GA
30333. Phone: (404) 639-2186. Fax: (404) 639-0049. E-mail:
ppellett{at}cdc.gov.
 |
REFERENCES |
| 1.
|
Bernard, P. S.,
M. J. Lay, and C. T. Wittwer.
1998.
Integrated amplification and detection of the c677T point mutation in the methylenetetrahydrofolate reductase gene by fluorescence resonance energy transfer and probe melting curves.
Anal. Biochem.
255:101-107[CrossRef][Medline].
|
| 2.
|
Diamond, C.,
S. J. Brodie,
J. N. Krieger,
M. L. Huang,
D. M. Koelle,
K. Diem,
D. Muthui, and L. Corey.
1998.
Human herpesvirus 8 in the prostate glands of men with Kaposi's sarcoma.
J. Virol.
72:6223-6227[Abstract/Free Full Text].
|
| 3.
|
Diamond, C.,
M. L. Huang,
D. H. Kedes,
C. Speck,
G. W. J. Rankin,
D. Ganem,
R. W. Coombs,
T. M. Rose,
J. N. Krieger, and L. Corey.
1997.
Absence of detectable human herpesvirus 8 in the semen of human immunodeficiency virus-infected men without Kaposi's sarcoma.
J. Infect. Dis.
176:775-777[Medline].
|
| 4.
|
Lallemand, F.,
N. Desire,
W. Rozenbaum,
J. C. Nicholas, and V. Marechal.
2000.
Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay.
J. Clin. Microbiol.
38:1404-1408[Abstract/Free Full Text].
|
| 5.
|
Lay, M. J., and C. T. Wittwer.
1997.
Real time fluorescence genotyping of factor V Leiden during rapid-cycle PCR.
Clin. Chem.
43:2262-2267[Abstract/Free Full Text].
|
| 6.
|
Lock, M. J.,
P. D. Griffiths, and V. C. Emery.
1997.
Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8.
J. Virol. Methods
64:19-26[CrossRef][Medline].
|
| 7.
|
Mendez, J. C.,
G. W. Procop,
M. J. Espy,
C. V. Paya, and T. F. Smith.
1998.
Detection and semiquantitative analysis of human herpesvirus 8 DNA in specimens from patients with Kaposi's sarcoma.
J. Clin. Microbiol.
36:2220-2222[Abstract/Free Full Text].
|
| 8.
|
Meng, Y.-X., and P. E. Pellett.
1999.
Herpesviruses 6, 7, and 8, p. 269-296.
In
R. Ahmed, and I. Chen (ed.), Persistent viral infections. John Wiley & Sons, Ltd., Sussex, England.
|
| 9.
|
Neipel, F.,
J. C. Albrecht,
A. Ensser,
Y. Q. Huang,
J. J. Li,
A. E. Friedman-Kien, and B. Fleckenstein.
1997.
Human herpesvirus 8 encodes a homolog of interleukin-6.
J. Virol.
71:839-842[Abstract].
|
| 10.
|
Nitsche, A.,
N. Steuer,
C. A. Schmidt,
O. Landt,
H. Ellerbrok,
G. Pauli, and W. Siegert.
2000.
Detection of human cytomegalovirus DNA by real-time quantitative PCR.
J. Clin. Microbiol.
38:2734-2737[Abstract/Free Full Text].
|
| 11.
|
O'Leary, J.,
M. Kennedy,
D. Howells,
I. Silva,
V. Uhlmann,
K. Luttich,
S. Biddolph,
S. Lucas,
J. Russell,
N. Bermingham,
M. O'Donovan,
M. Ring,
C. Kenny,
M. Sweeney,
O. Sheils,
C. Martin,
S. Picton, and K. Gatter.
2000.
Cellular localisation of HHV-8 in Castleman's disease: is there a link with lymph node vascularity?
Mol. Pathol.
53:69-76[Abstract/Free Full Text].
|
| 12.
|
O'Leary, J. J.,
M. Kennedy,
K. Luttich,
V. Uhlmann,
I. Silva,
J. Russell,
O. Sheils,
M. Ring,
M. Sweeney,
C. Kenny,
N. Bermingham,
C. Martin,
M. O'Donovan,
D. Howells,
S. Picton, and S. B. Lucas.
2000.
Localisation of HHV-8 in AIDS related lymphadenopathy.
Mol. Pathol.
53:43-47[Abstract/Free Full Text].
|
| 13.
|
Pellett, P. E., and S. C. Dollard.
2000.
Human herpesviruses 6, 7, and 8, p. 450-471.
In
S. Specter, R. L. Hodinka, and S. A. Young (ed.), Clinical virology manual. ASM Press, Washington, D.C.
|
| 14.
|
Russo, J. J.,
R. A. Bohenzky,
M. C. Chien,
J. Chen,
M. Yan,
D. Maddalena,
J. P. Parry,
D. Peruzzi,
I. S. Edelman,
Y. Chang, and P. S. Moore.
1996.
Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).
Proc. Natl. Acad. Sci. USA
93:14862-14867[Abstract/Free Full Text].
|
| 15.
|
Schulz, T. F.
1999.
Epidemiology of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8.
Adv. Cancer Res.
76:121-160[Medline].
|
| 16.
|
Spira, T. J.,
L. Lam,
S. C. Dollard,
Y. X. Meng,
C. P. Pau,
J. B. Black,
D. Burns,
B. Cooper,
M. Hamid,
J. Huong,
K. Kite-Powell, and P. E. Pellett.
2000.
Comparison of serologic assays and PCR for diagnosis of human herpesvirus 8 infection.
J. Clin. Microbiol.
38:2174-2180[Abstract/Free Full Text].
|
| 17.
|
Tyagi, S., and F. Kramer.
1996.
Molecular beacons: probes that fluoresce upon hybridization.
Nat. Biotechnol.
14:303-308[CrossRef][Medline].
|
Journal of Clinical Microbiology, October 2001, p. 3537-3540, Vol. 39, No. 10
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.10.3537-3540.2001
This article has been cited by other articles:
-
Dalton-Griffin, L., Wilson, S. J., Kellam, P.
(2009). X-Box Binding Protein 1 Contributes to Induction of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle under Hypoxic Conditions. J. Virol.
83: 7202-7209
[Abstract]
[Full Text]
-
Rappocciolo, G., Hensler, H. R., Jais, M., Reinhart, T. A., Pegu, A., Jenkins, F. J., Rinaldo, C. R.
(2008). Human Herpesvirus 8 Infects and Replicates in Primary Cultures of Activated B Lymphocytes through DC-SIGN. J. Virol.
82: 4793-4806
[Abstract]
[Full Text]
-
Perry, S. T., Compton, T.
(2006). Kaposi's Sarcoma-Associated Herpesvirus Virions Inhibit Interferon Responses Induced by Envelope Glycoprotein gpK8.1. J. Virol.
80: 11105-11114
[Abstract]
[Full Text]
-
Rappocciolo, G., Jenkins, F. J., Hensler, H. R., Piazza, P., Jais, M., Borowski, L., Watkins, S. C., Rinaldo, C. R. Jr
(2006). DC-SIGN Is a Receptor for Human Herpesvirus 8 on Dendritic Cells and Macrophages. J. Immunol.
176: 1741-1749
[Abstract]
[Full Text]
-
Su, C C, Li, C F, Liao, Y L, Lin, C N, Lu, J J
(2005). Immunohistochemical and molecular assessment of human herpesvirus type 8 in gastrointestinal tumours. J. Clin. Pathol.
58: 856-859
[Abstract]
[Full Text]
-
Martro, E., Cannon, M. J., Dollard, S. C., Spira, T. J., Laney, A. S., Ou, C.-Y., Pellett, P. E.
(2004). Evidence for both Lytic Replication and Tightly Regulated Human Herpesvirus 8 Latency in Circulating Mononuclear Cells, with Virus Loads Frequently below Common Thresholds of Detection. J. Virol.
78: 11707-11714
[Abstract]
[Full Text]
-
Luna, R. E., Zhou, F., Baghian, A., Chouljenko, V., Forghani, B., Gao, S.-J., Kousoulas, K. G.
(2004). Kaposi's Sarcoma-Associated Herpesvirus Glycoprotein K8.1 Is Dispensable for Virus Entry. J. Virol.
78: 6389-6398
[Abstract]
[Full Text]
-
Inoue, N., Winter, J., Lal, R. B., Offermann, M. K., Koyano, S.
(2003). Characterization of Entry Mechanisms of Human Herpesvirus 8 by Using an Rta-Dependent Reporter Cell Line. J. Virol.
77: 8147-8152
[Abstract]
[Full Text]
-
Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M.
(2003). Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev.
67: 175-212
[Abstract]
[Full Text]
-
Broccolo, F., Locatelli, G., Sarmati, L., Piergiovanni, S., Veglia, F., Andreoni, M., Butto, S., Ensoli, B., Lusso, P., Malnati, M. S.
(2002). Calibrated Real-Time PCR Assay for Quantitation of Human Herpesvirus 8 DNA in Biological Fluids. J. Clin. Microbiol.
40: 4652-4658
[Abstract]
[Full Text]